Hepatic Impairment Study
NCT00829231
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
45
Enrollment
INDUSTRY
Sponsor class
Conditions
Liver Disease
Interventions
DRUG:
Sorafenib (Nexavar, BAY43-9006)
DRUG:
Sorafenib (Nexavar, BAY43-9006)
DRUG:
Sorafenib (Nexavar, BAY43-9006)
Sponsor
Bayer